
---
title: '成都先导与海昶生物达成项目合作，共同开发抗肿瘤小核酸新药'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=1714'
author: 证券时报网
comments: false
date: Mon, 04 Jul 2022 12:30:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=1714'
---

<div>   
<p>证券时报e公司讯，近日，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS688222" style="color: #2f67d1;text-decoration: none;" code="688222" target="_blank">成都先导</a>与海昶生物达成小核酸新药研发合作协议，双方将共同开发基于未披露靶点的用于肿瘤治疗的小核酸新药。</p>

                  
</div>
            